Other languages ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
8.94 ^USD	-1.76%		+1.36%	+63.14%

Jun. 13	Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing	MT
May. 09	ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing	Jun. 13
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	Apr. 30
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	Apr. 30
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	Apr. 10
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	Apr. 03
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	Apr. 03
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study	Feb. 26
ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA?s Complete Response Letter	Feb. 20
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
ARS Pharmaceuticals Says US Food and Drug Administration Schedules Type A Meeting on Allergy Spray for End of October	23-10-06
Ars Pharmaceuticals, Inc. Announces Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology	23-10-03
Ars Pharmaceuticals Insider Bought Shares Worth $319,954, According to a Recent SEC Filing	23-10-02
Sector Update: Health Care Stocks Declining Late Thursday Afternoon	23-09-21
Sector Update: Health Care	23-09-21
ARS Pharmaceuticals Likely to Get Approval for Epinephrine Nasal Spray in H2 2024, Wedbush Says	23-09-21
Sector Update: Health Care Stocks Advancing Late Wednesday Afternoon	23-09-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Other languages

Filters